Stem cell therapies: from promise to clinical reality
The regulatory pathway for stem cell therapies, while rigorous, has become increasingly navigable as scientific understanding deepens and clinical evidence accumulates. Between 2023 and 2025, several milestone approvals reshaped the field.
Breakthrough applications in neurological disorders
Parkinson's disease has emerged as a particularly promising target for stem cell intervention. Two landmark phase I/II trials recently reported their findings. In Japan, a team at Kyoto University transplanted dopaminergic progenitors derived from induced pluripotent stem cells into seven patients — the grafted cells survived, produced dopamine, and did not form tumours over 24 months. A separate US trial using human embryonic stem cell-derived dopaminergic neurons showed similar safety profiles, with high-dose patients experiencing approximately 50% reduction in motor symptoms at 18 and 24 months compared to baseline.
Diverse sources, distinct advantages
The stem cell field encompasses multiple cell types, each suited to different applications. Embryonic stem cells offer pluripotent capacity. Induced pluripotent stem cells provide similar differentiation potential while avoiding some ethical concerns. Mesenchymal stem cells have shown therapeutic effects primarily through paracrine mechanisms — secreting factors that modulate inflammation and promote tissue repair. The selection of cell source depends on the therapeutic goal, manufacturing considerations, regulatory requirements, and the specific disease mechanism being targeted.
Clinical trial design considerations
Conducting stem cell trials requires navigating unique operational challenges. The cellular products themselves demand specialised handling, with requirements for cold chain management, rapid processing, and precise timing of administration. Patient recruitment requires candidates to meet stringent eligibility criteria, often including specific disease stages. Manufacturing complexity further distinguishes stem cell trials from conventional drug studies — autologous products require individual manufacturing for each patient, while allogeneic products may require immunosuppression protocols.
Georgia: a case study in emerging research capacity
Georgia offers a useful case study in how an emerging research environment can develop the regulatory alignment, infrastructure, and operational capacity required for stem cell trials. The country has now reached approximately a decade of experience in stem cell transplantation, providing an operational foundation for more advanced cellular therapy trials. The combination of modern medical infrastructure, a qualified investigator pool, and regulatory pathways increasingly aligned with international standards creates conditions under which sponsors can consider Georgia as a viable site for cellular therapy programmes.
Prepared by Paspigioni team: Marika Gergedava, MD and Nina Biblaia